{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:51:15Z","timestamp":1786935075154,"version":"build-2736575974"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00467-021-05076-x","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T03:50:46Z","timestamp":1619754646000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Fabry disease and kidney involvement: starting from childhood to understand the future"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-4637","authenticated-orcid":false,"given":"Roberto","family":"Chimenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cuppari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Ceravolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Concolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Monardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lacquaniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"5076_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30","journal-title":"Orphanet J Rare Dis"},{"key":"5076_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"5076_CR3","doi-asserted-by":"publisher","first-page":"85895","DOI":"10.18632\/oncotarget.13135","volume":"7","author":"MT Di Martino","year":"2016","unstructured":"Di Martino MT, Scionti F, Sestito S, Nicoletti A, Arbitrio M, Hiram Guzzi P, Talarico V, Altomare F, Sanseviero MT, Agapito G, Pisani A, Riccio E, Borrelli O, Concolino D, Pensabene L (2016) Genetic variants associated with gastrointestinal symptoms in Fabry disease. Oncotarget 7:85895\u201385904","journal-title":"Oncotarget"},{"key":"5076_CR4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","volume":"68","author":"V Favalli","year":"2016","unstructured":"Favalli V, Disabella E, Molinaro M, Tagliani M, Scarabotto A, Serio A, Grasso M, Narula N, Giorgianni C, Caspani C, Concardi M, Agozzino M, Giordano C, Smirnova A, Kodama T, Giuliani L, Antoniazzi E, Borroni RG, Vassallo C, Mangione F, Scelsi L, Ghio S, Pellegrini C, Zedde M, Fancellu L, Sechi G, Ganau A, Piga S, Colucci A, Concolino D, Di Mascio MT, Toni D, Diomedi M, Rapezzi C, Biagini E, Marini M, Rasura M, Melis M, Nucera A, Guidetti D, Mancuso M, Scoditti U, Cassini P, Narula J, Tavazzi L, Arbustini E (2016) Genetic screening of Anderson-Fabry disease in probands referred from multispecialty clinics. J Am Coll Cardiol 68:1037\u20131050","journal-title":"J Am Coll Cardiol"},{"key":"5076_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Sanchez-Ni\u00f1o MD, Politei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A (2013) Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 8:116","journal-title":"Orphanet J Rare Dis"},{"key":"5076_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ndt\/gfx009","volume":"33","author":"A Pisani","year":"2018","unstructured":"Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, Bruzzese D, Feriozzi S, Imbriaco M, Tedeschi E, Cocozza S, De Rosa D, Mignani R, Veroux M, Battaglia Y, Concolino D, Sestito S, Pieruzzi F, Caroti L, Manna R, Zizzo C, Santangelo M, Sabbatini M, Riccio E (2018) Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant 33:318\u2013323","journal-title":"Nephrol Dial Transplant"},{"key":"5076_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52:353\u2013358","journal-title":"J Med Genet"},{"key":"5076_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, Wilcox WR, Fabry Pediatric Expert Panel (2016) The management and treatment of children with Fabry disease: a United States-based perspective. Mol Genet Metab 117:104\u2013113","journal-title":"Mol Genet Metab"},{"key":"5076_CR9","doi-asserted-by":"publisher","first-page":"107558","DOI":"10.18632\/oncotarget.22505","volume":"8","author":"F Scionti","year":"2017","unstructured":"Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K, Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D, Pensabene L (2017) Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. Oncotarget 8:107558\u2013107564","journal-title":"Oncotarget"},{"key":"5076_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"5076_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151\u2013156","journal-title":"Hum Genet"},{"key":"5076_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"5076_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J (2015) Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 166:172\u2013177","journal-title":"J Pediatr"},{"key":"5076_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tcm.2017.10.001","volume":"28","author":"TR Hsu","year":"2018","unstructured":"Hsu TR, Niu DM (2018) Fabry disease: review and experience during newborn screening. Trends Cardiovasc Med 28:274\u2013281","journal-title":"Trends Cardiovasc Med"},{"key":"5076_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123:416\u2013427","journal-title":"Mol Genet Metab"},{"key":"5076_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89:44\u201354","journal-title":"Clin Genet"},{"key":"5076_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/mgg3.389","volume":"6","author":"DP Germain","year":"2018","unstructured":"Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Mar\u00f3di L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A (2018) Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med 6:492\u2013503","journal-title":"Mol Genet Genomic Med"},{"key":"5076_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Weidemann F, Kurschat C, Canaan-K\u00fchl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Kr\u00e4mer J, Blaschke D, Wanner C, Brand SM, Brand E (2016) Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis 11:54","journal-title":"Orphanet J Rare Dis"},{"key":"5076_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397\u20131405","journal-title":"Hum Mutat"},{"key":"5076_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1\u20139","journal-title":"J Med Genet"},{"key":"5076_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86\u201392","journal-title":"Acta Paediatr"},{"key":"5076_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","volume":"30","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68\u201378","journal-title":"J Inherit Metab Dis"},{"key":"5076_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cge.12386","volume":"86","author":"A Pisani","year":"2014","unstructured":"Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, Riccio E (2014) The kidney in Fabry\u2019s disease. Clin Genet 86:301\u2013309","journal-title":"Clin Genet"},{"key":"5076_CR24","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","volume":"34","author":"CV Madsen","year":"2019","unstructured":"Madsen CV, Granqvist H, Petersen JH, Rasmussen \u00c5K, Lund AM, Oturai P, S\u00f8rensen SS, Feldt-Rasmussen U (2019) Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrol Dial Transplant 34:1525\u20131533","journal-title":"Nephrol Dial Transplant"},{"key":"5076_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2010.08.023","volume":"102","author":"YH Chien","year":"2011","unstructured":"Chien YH, Olivova P, Zhang XK, Chiang SC, Lee NC, Keutzer J, Hwu WL (2011) Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease. Mol Genet Metab 102:57\u201360","journal-title":"Mol Genet Metab"},{"key":"5076_CR26","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O\u2019Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933\u20131946","journal-title":"Kidney Int"},{"key":"5076_CR27","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1038\/ki.2008.522","volume":"111","author":"R Torra","year":"2008","unstructured":"Torra R (2008) Renal manifestations in Fabry disease and therapeutic options. Kidney Int Suppl 111:S29\u2013S32","journal-title":"Kidney Int Suppl"},{"key":"5076_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","volume":"112","author":"A Hag\u00e8ge","year":"2019","unstructured":"Hag\u00e8ge A, R\u00e9ant P, Habib G, Damy T, Barone-Rochette G, Soulat G, Donal E, Germain DP (2019) Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis 112:278\u2013287","journal-title":"Arch Cardiovasc Dis"},{"key":"5076_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1159\/000369309","volume":"129","author":"C T\u00f8ndel","year":"2015","unstructured":"T\u00f8ndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, Svarstad E (2015) Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron 129:1621","journal-title":"Nephron"},{"key":"5076_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137\u2013148","journal-title":"J Am Soc Nephrol"},{"key":"5076_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2215\/CJN.08091109","volume":"5","author":"U Ramaswami","year":"2010","unstructured":"Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG (2010) Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol 5:365\u2013370","journal-title":"Clin J Am Soc Nephrol"},{"key":"5076_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfs526","volume":"28","author":"W Terryn","year":"2013","unstructured":"Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C (2013) Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 28:505\u2013517","journal-title":"Nephrol Dial Transplant"},{"key":"5076_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int 64:801\u2013807","journal-title":"Kidney Int"},{"key":"5076_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s10157-005-0369-4","volume":"9","author":"M Ichinose","year":"2005","unstructured":"Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y (2005) Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 9:228\u2013232","journal-title":"Clin Exp Nephrol"},{"key":"5076_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.ajkd.2005.01.036","volume":"45","author":"M Cybulla","year":"2005","unstructured":"Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:82\u201389","journal-title":"Am J Kidney Dis"},{"key":"5076_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JMFG, Hollak CEM (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201\u2013203","journal-title":"Clin Chim Acta"},{"key":"5076_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","volume":"97","author":"C Auray-Blais","year":"2009","unstructured":"Auray-Blais C, Millington DS, Barr C, Young SP, Mills K, Clarke JT (2009) Gb(3)\/creatinine biomarkers for Fabry disease: issues to consider. Mol Genet Metab 97:237","journal-title":"Mol Genet Metab"},{"key":"5076_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2174\/187152506778520718","volume":"4","author":"S Bekri","year":"2008","unstructured":"Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F (2008) The role of ceramide rihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry Disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 4:289\u2013297","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"5076_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","volume":"120","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120:57\u201361","journal-title":"Mol Genet Metab"},{"key":"5076_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H (2018) Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy. Clin Exp Nephrol 22:843\u2013849","journal-title":"Clin Exp Nephrol"},{"key":"5076_CR41","first-page":"1","volume":"33","author":"R Chimenz","year":"2019","unstructured":"Chimenz R (2019) Focus on pediatric nephrology. J Biol Regul Homeost Agents 33:1","journal-title":"J Biol Regul Homeost Agents"},{"key":"5076_CR42","first-page":"59","volume":"33","author":"S Sestito","year":"2019","unstructured":"Sestito S, Falvo F, Sallemi A, Petrisano M, Scuderi MG, Tarsitano F, D\u2019Angelo G, Betta P, Roppa K, Parisi F, Pensabene L, Fede C, Chimenz R, Concolino D (2019) Renal involvement in paediatric Fabry disease. J Biol Regul Homeost Agents 33:59\u201363","journal-title":"J Biol Regul Homeost Agents"},{"key":"5076_CR43","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1093\/ndt\/gfr084","volume":"26","author":"M Selvarajah","year":"2011","unstructured":"Selvarajah M, Nicholls K, Hewitson TD, Becker GJ (2011) Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique. Nephrol Dial Transplant 26:3195\u20133202","journal-title":"Nephrol Dial Transplant"},{"key":"5076_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13730-012-0038-x","volume":"2","author":"T Nakamichi","year":"2013","unstructured":"Nakamichi T, Miyazaki M, Nakayama K, Sato M, Akiu N, Sato T, Sato H, Ito S (2013) Fabry\u2019s disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep 2:49\u201352","journal-title":"CEN Case Rep"},{"key":"5076_CR45","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2169\/internalmedicine.3813-19","volume":"59","author":"Y Aoyama","year":"2020","unstructured":"Aoyama Y, Ushio Y, Yokoyama T, Taneda S, Makabe S, Nishida M, Manabe S, Sato M, Kataoka H, Tsuchiya K, Nitta K, Mochizuki T (2020) Urinary Mulberry cells as a biomarker of the efficacy of enzyme replacement therapy for Fabry Disease. Intern Med 59:971\u2013976","journal-title":"Intern Med"},{"key":"5076_CR46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5935\/0101-2800.20130043","volume":"35","author":"AR Sabino","year":"2013","unstructured":"Sabino AR, Teixeira Vde P, Nishida SK, Sass N, Mansur JB, Kirsztajn GM (2013) Detection of podocyturia in patients with lupus nephritis. J Bras Nefrol 35:252\u2013258","journal-title":"J Bras Nefrol"},{"key":"5076_CR47","doi-asserted-by":"publisher","first-page":"22379","DOI":"10.1038\/s41598-020-79997-2","volume":"10","author":"A Mella","year":"2020","unstructured":"Mella A, Deambrosis I, Mingozzi S, Colla L, Burdese M, Giaretta F, Bruno S, Camussi G, Boaglio E, Dolla C, Clari R, Biancone L (2020) Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy. Sci Rep 10:22379","journal-title":"Sci Rep"},{"key":"5076_CR48","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nefro.2018.05.009","volume":"39","author":"M Liern","year":"2019","unstructured":"Liern M, Collazo A, Valencia M, Fainboin A, Isse L, Costales-Collaguazo C, Ochoa F, Vallejo G, Zotta E (2019) Podocyturia in paediatric patients with Fabry disease. Nefrologia 39:177\u2013183","journal-title":"Nefrologia"},{"key":"5076_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","volume":"29","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, Paulero M, Rengel T, Ar\u00e1oz A, Forrester M, Lombi F, Pomeranz V, Iriarte R, Young P, Muryan A, Zotta E (2016) Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J Nephrol 29:791\u2013797","journal-title":"J Nephrol"},{"key":"5076_CR50","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1039\/C4MB00707G","volume":"11","author":"V Matafora","year":"2015","unstructured":"Matafora V, Cuccurullo M, Beneduci A, Petrazzuolo O, Simeone A, Anastasio P, Mignani R, Feriozzi S, Pisani A, Comotti C, Bachi A, Capasso G (2015) Early markers of Fabry disease revealed by proteomics. Mol Biosyst 11:1543\u20131551","journal-title":"Mol Biosyst"},{"key":"5076_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jmedgenet-2019-106030","volume":"57","author":"ID Doykov","year":"2020","unstructured":"Doykov ID, Heywood WE, Nikolaenko V, \u015apiewak J, H\u00e4llqvist J, Clayton PT, Mills P, Warnock DG, Nowak A, Mills K (2020) Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease. J Med Genet 57:38\u201347","journal-title":"J Med Genet"},{"key":"5076_CR52","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/jcm9051325","volume":"9","author":"A Tebani","year":"2020","unstructured":"Tebani A, Mauhin W, Abily-Donval L, Lesueur C, Berger MG, Nadjar Y, Berger J, Benveniste O, Lamari F, Lafor\u00eat P, Noel E, Marret S, Lidove O, Bekri S (2020) Proteomics-based analysis reveals predictive biological patterns in Fabry Disease. J Clin Med 9:1325","journal-title":"J Clin Med"},{"key":"5076_CR53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000492157","volume":"48","author":"D Zhang","year":"2018","unstructured":"Zhang D, Zhang J, Liang S, Wang J, Liu Z (2018) Clinic-pathologic features and renal outcome of Fabry disease: data from a Chinese cohort. Am J Nephrol 48:137\u2013146","journal-title":"Am J Nephrol"},{"key":"5076_CR54","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C T\u00f8ndel","year":"2008","unstructured":"T\u00f8ndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767\u2013776","journal-title":"Am J Kidney Dis"},{"key":"5076_CR55","doi-asserted-by":"publisher","first-page":"e0124987","DOI":"10.1371\/journal.pone.0124987","volume":"10","author":"FA Wijburg","year":"2015","unstructured":"Wijburg FA, B\u00e9nichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini C, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, T\u00f8ndel C, Tylki-Szyma\u0144ska A, Ramaswami U (2015) Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One 10:e0124987","journal-title":"PLoS One"},{"key":"5076_CR56","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","volume":"4","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ (2004) Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 4:1167\u20131176","journal-title":"Expert Opin Biol Ther"},{"key":"5076_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"5076_CR58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neulet.2016.06.051","volume":"629","author":"C Simoncini","year":"2016","unstructured":"Simoncini C, Chico L, Concolino D, Sestito S, Fancellu L, Boadu W, Sechi GP, Feliciani C, Gnarra M, Zampetti A, Salviati A, Scarpelli M, Orsucci D, Bonuccelli U, Siciliano G, Mancuso M (2016) Mitochondrial DNA haplogroups may influence Fabry disease phenotype. Neurosci Lett 629:58\u201361","journal-title":"Neurosci Lett"},{"key":"5076_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, T\u00f8ndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE (2015) Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 10:36","journal-title":"Orphanet J Rare Dis"},{"key":"5076_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M (2017) Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab 121:157\u2013161","journal-title":"Mol Genet Metab"},{"key":"5076_CR61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00109-010-0686-2","volume":"89","author":"EC Batista","year":"2010","unstructured":"Batista EC, Carvalho LR, Casarini DE, Carmona AK, dos Santos EL, da Silva ED, dos Santos RA, Nakaie CR, Rojas MV, de Oliveira SM, Bader M, D\u2019Almeida V, Martins AM, de Picoly Souza K, Pesquero JB (2010) ACE activity is modulated by the enzyme \u03b1-galactosidase A. J Mol Med 89:65\u201374","journal-title":"J Mol Med"},{"key":"5076_CR62","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A (2010) Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature. Genet Med 12:668\u2013679","journal-title":"Genet Med"},{"key":"5076_CR63","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E (2018) Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol 29:2265\u20132278","journal-title":"J Am Soc Nephrol"},{"key":"5076_CR64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, Ruderfer I, Aviezer D, Shaaltiel Y (2015) Characterization of a chemically modified plant cell culture expressed human \u03b1-galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab 114:259\u2013267","journal-title":"Mol Genet Metab"},{"key":"5076_CR65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, Jennette CJ, Maegawa G, Boyadjiev SA, Gonzalez D, Nicholls K, Tuffaha A, Atta MG, Rup B, Charney MR, Paz A, Szlaifer M, Alon S, Brill-Almon E, Chertkoff R, Hughes D (2019) Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1\/2 clinical trial. J Inherit Metab Dis 42:534\u2013544","journal-title":"J Inherit Metab Dis"},{"key":"5076_CR66","doi-asserted-by":"publisher","first-page":"110779","DOI":"10.1016\/j.biopha.2020.110779","volume":"131","author":"S Kant","year":"2020","unstructured":"Kant S, Atta MG (2020) Therapeutic advances in Fabry disease: the future awaits. Biomed Pharmacother 131:110779","journal-title":"Biomed Pharmacother"},{"key":"5076_CR67","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1042\/BJ20070479","volume":"406","author":"S Ishii","year":"2007","unstructured":"Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ (2007) Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406:285\u2013295","journal-title":"Biochem J"},{"key":"5076_CR68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K (2020) Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab 131:219\u2013228","journal-title":"Mol Genet Metab"},{"key":"5076_CR69","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2020","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E (2020) Current and investigational therapeutics for Fabry disease. Kidney Int Rep 5:407\u2013413","journal-title":"Kidney Int Rep"},{"key":"5076_CR70","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.1321","volume":"105","author":"J M\u00fcntze","year":"2019","unstructured":"M\u00fcntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, Hu K, Lorenz K, Frantz S, Wanner C, Nordbeck P (2019) Oral chaperone therapy Migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther 105:1224\u20131233","journal-title":"Clin Pharmacol Ther"},{"key":"5076_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1566523218666180404161315","volume":"18","author":"I Simonetta","year":"2018","unstructured":"Simonetta I, Tuttolomondo A, Di Chiara T, Miceli S, Vogiatzis D, Corpora F, Pinto A (2018) Genetics and gene therapy of Anderson-Fabry disease. Curr Gene Ther 18:96\u2013106","journal-title":"Curr Gene Ther"},{"key":"5076_CR72","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","volume":"27","author":"AP Ruiz de Garibay","year":"2013","unstructured":"Ruiz de Garibay AP, Solin\u00eds MA, Rodr\u00edguez-Gasc\u00f3n A (2013) Gene therapy for fabry disease: a review of the literature. BioDrugs 27:237\u2013246","journal-title":"BioDrugs"},{"key":"5076_CR73","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/14712598.2019.1607837","volume":"19","author":"MS Nagree","year":"2019","unstructured":"Nagree MS, Scalia S, McKillop WM, Medin JA (2019) An update on gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 19:655\u2013670","journal-title":"Expert Opin Biol Ther"},{"key":"5076_CR74","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122\u2013138","journal-title":"Medicine"},{"key":"5076_CR75","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jama.1975.03250020022018","volume":"232","author":"BA Barnes","year":"1975","unstructured":"Barnes BA, Bergan JJ (1975) Advisory Committee to the Renal Transplant Registry. Renal transplantation in congenital and metabolic diseases. A report from the ASC\/NIH Renal Transplant Registry. JAMA 232:148\u2013153","journal-title":"JAMA"},{"key":"5076_CR76","first-page":"57","volume":"13","author":"SE Maizel","year":"1981","unstructured":"Maizel SE, Simmons RL, Kjellstrand C, Fryd DS (1981) Ten-year experience in renal transplantation for Fabry\u2019s disease. Transplant Proc 13:57\u201359","journal-title":"Transplant Proc"},{"key":"5076_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","volume":"11","author":"D Tsakiris","year":"1996","unstructured":"Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F (1996) Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11:4\u201320","journal-title":"Nephrol Dial Transplant"},{"key":"5076_CR78","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","volume":"69","author":"A Ojo","year":"2000","unstructured":"Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B (2000) Excellent outcome of renal transplantation in patients with Fabry\u2019s disease. Transplantation 69:2337\u20132339","journal-title":"Transplantation"},{"key":"5076_CR79","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1097\/TP.0000000000002252","volume":"102","author":"S Ers\u00f6zl\u00fc","year":"2018","unstructured":"Ers\u00f6zl\u00fc S, Desnick RJ, Huynh-Do U, Canaan-K\u00fchl S, Barbey F, Genitsch V, Mueller TF, Cheetham M, Flammer AJ, Schaub S, Nowak A (2018) Long-term outcomes of kidney transplantation in Fabry disease. Transplantation 102:1924\u20131933","journal-title":"Transplantation"},{"key":"5076_CR80","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","volume":"23","author":"R Mignani","year":"2008","unstructured":"Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L (2008) Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 23:1628\u20131635","journal-title":"Nephrol Dial Transplant"},{"key":"5076_CR81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","volume":"22","author":"M Cybulla","year":"2009","unstructured":"Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G, European FOS Investigators Group (2009) Kidney transplantation in patients with Fabry disease. Transpl Int 22:475\u2013481","journal-title":"Transpl Int"},{"key":"5076_CR82","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249\u2013255","journal-title":"Kidney Int"},{"key":"5076_CR83","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00467-009-1137-6","volume":"24","author":"P Cochat","year":"2009","unstructured":"Cochat P, Fargue S, Mestrallet G, Jungraithmayr T, Koch-Nogueira P, Ranchin B, Zimmerhackl LB (2009) Disease recurrence in pediatric renal transplantation. Pediatr Nephrol 24:2097\u20132108","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05076-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05076-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05076-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T01:24:51Z","timestamp":1698974691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05076-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5076"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05076-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have declared that no conflict of interest exists.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}